
    
      After being informed about the study and potential risks, all patients giving written
      informed consent will undergo a screening period. Maximum allowable time between first
      screening procedure and first administration of study treatment will be 42 days.

      Subjects will have a 28 day run-in period consisting of 2 visits at week -4 and week -2.

      Subjects will have a Baseline day 1 visit. Study medication will commerce on the day
      following this visit.

      Additional visits will be at the following time points: week 4, week 8, week 12, week 16,
      week 24, week 36, week 48, week 52, week 56, week 60, week 72, week 84 and week 96.
    
  